Compare L & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | L | ZBH |
|---|---|---|
| Founded | 1969 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 19.5B |
| IPO Year | 1998 | 2001 |
| Metric | L | ZBH |
|---|---|---|
| Price | $110.37 | $95.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $104.56 |
| AVG Volume (30 Days) | 520.0K | ★ 1.8M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | 0.23% | ★ 0.99% |
| EPS Growth | ★ 24.34 | N/A |
| EPS | ★ 7.97 | 3.55 |
| Revenue | ★ $18,454,000,000.00 | $8,231,500,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | N/A | $3.75 |
| P/E Ratio | ★ $13.82 | $27.18 |
| Revenue Growth | 5.39 | ★ 7.20 |
| 52 Week Low | $82.49 | $84.59 |
| 52 Week High | $114.90 | $108.29 |
| Indicator | L | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 59.68 |
| Support Level | $107.84 | $93.29 |
| Resistance Level | $112.32 | $95.31 |
| Average True Range (ATR) | 1.98 | 1.99 |
| MACD | 0.45 | 0.79 |
| Stochastic Oscillator | 82.26 | 73.41 |
Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.